{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:58:17Z","timestamp":1781607497863,"version":"3.54.5"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003504","name":"University of the Western Cape","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003504","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of metabolic dysfunction-associated steatotic liver disease (MASLD), and its progression to metabolic dysfunction-associated steatohepatitis (MASH), is triggered and aggravated by obesity and related metabolic diseases. Hence, therapeutic strategies for obesity and diabetes are employed in the clinical management of MASLD and MASH. However, most of the antiobesity and antidiabetic drugs have been withdrawn from the market due to a lack of sustainable drug effects and undesirable side effects. Prior to the approval of resmetirom by the United States Food and Drug Administration in 2024, there were no specific treatments for MASLD and MASH. Therefore, this stresses the importance of developing improved and effective disease-specific treatment strategies to combat MASLD and MASH. MASLD and MASH are characterized by hepatocyte damage, chronic low-grade systemic inflammation, and abnormalities in lipid metabolism. Inflammation and oxidative stress are key mediators of high-fat diet-induced steatohepatitis and obesity. Identifying biomarkers involved in these processes could aid in the development of targeted treatment for MASLD and MASH. In this review, targeted treatment strategies for obesity are discussed in relation to the possibility of the same being used in obesity-related steatotic liver diseases (SLDs).<\/jats:p>","DOI":"10.1007\/s11154-025-09980-7","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:23:25Z","timestamp":1750811005000},"page":"955-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis"],"prefix":"10.1007","volume":"26","author":[{"given":"Thendo I.","family":"Mabuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R. S.","family":"Sibuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewale O.","family":"Fadaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervin","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abram M.","family":"Madiehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwazikwakhe B.","family":"Gabuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"9980_CR1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.85780","author":"ZA Sherif","year":"2019","unstructured":"Sherif ZA. The rise in the prevalence of nonalcoholic fatty liver disease and hepatocellular carcinoma. Nonalcoholic Fat Liver Disease - Update. 2019. https:\/\/doi.org\/10.5772\/intechopen.85780.","journal-title":"Nonalcoholic Fat Liver Disease - Update"},{"key":"9980_CR2","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.3390\/IJMS25115571","volume":"25","author":"LP Nendouvhada","year":"2024","unstructured":"Nendouvhada LP, Sibuyi NRS, Fadaka AO, Meyer S, Madiehe AM, Meyer M, et al. Phytonanotherapy for the treatment of metabolic Dysfunction-Associated steatotic liver disease. Int J Mol Sci. 2024;25:5571. https:\/\/doi.org\/10.3390\/IJMS25115571.","journal-title":"Int J Mol Sci"},{"key":"9980_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0959-9673.2006.00465.x","volume":"87","author":"QM Anstee","year":"2006","unstructured":"Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1\u201316. https:\/\/doi.org\/10.1111\/j.0959-9673.2006.00465.x.","journal-title":"Int J Exp Pathol"},{"key":"9980_CR4","doi-asserted-by":"publisher","first-page":"101185","DOI":"10.1016\/J.JHEPR.2024.101185","volume":"6","author":"F Carli","year":"2024","unstructured":"Carli F, Della Pepa G, Sabatini S, Vidal Puig A, Gastaldelli A. Lipid metabolism in MASLD and MASH: from mechanism to the clinic. JHEP Rep. 2024;6:101185. https:\/\/doi.org\/10.1016\/J.JHEPR.2024.101185.","journal-title":"JHEP Rep"},{"key":"9980_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.09.029","author":"P Gupta","year":"2016","unstructured":"Gupta P, Bala M, Gupta S, Dua A, Dabur R, Injeti E, et al. Efficacy and risk profile of anti-diabetic therapies: conventional vs traditional drugs\u2014A mechanistic revisit to understand their mode of action. Pharmacol Res. 2016. https:\/\/doi.org\/10.1016\/j.phrs.2016.09.029.","journal-title":"Pharmacol Res"},{"key":"9980_CR6","doi-asserted-by":"publisher","unstructured":"Mambrini SP, Grillo A, Colosimo S, Zarpellon F, Pozzi G, Furlan D, et al. Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility. Front Nutr. 2024;11. https:\/\/doi.org\/10.3389\/FNUT.2024.1426551.","DOI":"10.3389\/FNUT.2024.1426551"},{"key":"9980_CR7","doi-asserted-by":"publisher","unstructured":"Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14\u201330 https:\/\/doi.org\/10.1007\/s13679-020-00422-w1.","DOI":"10.1007\/s13679-020-00422-w1."},{"key":"9980_CR8","doi-asserted-by":"publisher","unstructured":"Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I. The cardiovascular safety of antiobesity drugs\u2014analysis of signals in the FDA adverse event report system database. Int J Obes. 2020;44. https:\/\/doi.org\/10.1038\/s41366-020-0544-4.","DOI":"10.1038\/s41366-020-0544-4"},{"key":"9980_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101882.","journal-title":"eClinicalMedicine"},{"key":"9980_CR10","doi-asserted-by":"publisher","unstructured":"Kokkorakis M, Boutari C, Hill MA, Kotsis V, Loomba R, Sanyal AJ, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism. 2024;154. https:\/\/doi.org\/10.1016\/j.metabol.2024.155835.","DOI":"10.1016\/j.metabol.2024.155835"},{"key":"9980_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01119-3","volume":"7","author":"X Xu","year":"2022","unstructured":"Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH). Signal Transduct Target Therapy 2022. 2022;7:1. https:\/\/doi.org\/10.1038\/s41392-022-01119-3.","journal-title":"Signal Transduct Target Therapy 2022"},{"key":"9980_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03295-4","author":"F Mahmoudian","year":"2024","unstructured":"Mahmoudian F, Ahmari A, Shabani S, Sadeghi B, Fahimirad S, Fattahi F. Aptamers as an approach to targeted cancer therapy. Cancer Cell Int. 2024. https:\/\/doi.org\/10.1186\/s12935-024-03295-4.","journal-title":"Cancer Cell Int"},{"key":"9980_CR13","doi-asserted-by":"publisher","unstructured":"Tee KB, Ibrahim L, Hashim NM, Saiman MZ, Zakaria ZH, Huri HZ. Pharmacokinetic\u2013Pharmacometabolomic approach in Early-Phase clinical trials: A way forward for targeted therapy in type 2 diabetes. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14061268.","DOI":"10.3390\/pharmaceutics14061268"},{"key":"9980_CR14","doi-asserted-by":"publisher","unstructured":"Chen X, He X, Gao R, Lan X, Zhu L, Chen K, et al. Aptamer-Functionalized Binary-Drug delivery system for synergetic obesity therapy. ACS Nano. 2022;16. https:\/\/doi.org\/10.1021\/acsnano.1c08690.","DOI":"10.1021\/acsnano.1c08690"},{"key":"9980_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00832-3","author":"A Herrero-Cervera","year":"2022","unstructured":"Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022. https:\/\/doi.org\/10.1038\/s41423-021-00832-3.","journal-title":"Cell Mol Immunol"},{"key":"9980_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116069","author":"T Dong","year":"2024","unstructured":"Dong T, Li J, Liu Y, Zhou S, Wei X, Hua H, et al. Roles of immune dysregulation in MASLD. Biomed Pharmacotherapy. 2024. https:\/\/doi.org\/10.1016\/j.biopha.2023.116069.","journal-title":"Biomed Pharmacotherapy"},{"key":"9980_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071338","author":"L Lei","year":"2021","unstructured":"Lei L, Mourabit HEI, Housset C, Cadoret A, Lemoinne S. Role of angiogenesis in the pathogenesis of Nafld. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10071338.","journal-title":"J Clin Med"},{"key":"9980_CR18","doi-asserted-by":"publisher","unstructured":"Balaban YH, Sumer H, Simsek H, Us D, Tatar G. Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF). Ann Hepatol. 2006;5. https:\/\/doi.org\/10.1016\/s1665-2681(19)32027-7.","DOI":"10.1016\/s1665-2681(19)32027-7"},{"key":"9980_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.655557","author":"XK Wang","year":"2021","unstructured":"Wang XK, Peng ZG. Targeting liver sinusoidal endothelial cells: an attractive therapeutic strategy to control inflammation in nonalcoholic fatty liver disease. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.655557.","journal-title":"Front Pharmacol"},{"key":"9980_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jconrel.2020.10.002","volume":"329","author":"R Hiradate","year":"2021","unstructured":"Hiradate R, Khalil IA, Matsuda A, Sasaki M, Hida K, Harashima H. A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the Browning of white adipose tissue. J Controlled Release. 2021;329:665\u201375.","journal-title":"J Controlled Release"},{"key":"9980_CR21","doi-asserted-by":"publisher","first-page":"2203286","DOI":"10.1002\/advs.202203286","volume":"9","author":"J Hong","year":"2022","unstructured":"Hong J, Kim Y. Fatty liver\/adipose tissue Dual-Targeting nanoparticles with Heme Oxygenase\u20101 inducer for amelioration of obesity, Obesity\u2010Induced type 2 diabetes, and steatohepatitis. Adv Sci. 2022;9:2203286.","journal-title":"Adv Sci"},{"key":"9980_CR22","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.metop.2021.100149","volume":"12","author":"P Zarghamravanbakhsh","year":"2021","unstructured":"Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open. 2021;12:100149.","journal-title":"Metabol Open"},{"key":"9980_CR23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(21)00275-2","volume":"6","author":"CW Spearman","year":"2021","unstructured":"Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, et al. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2021;6:1036\u201346. https:\/\/doi.org\/10.1016\/S2468-1253(21)00275-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9980_CR24","doi-asserted-by":"publisher","first-page":"e1375","DOI":"10.1016\/S2214-109X(19)30374-2","volume":"7","author":"HN Gouda","year":"2019","unstructured":"Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Burden of non-communicable diseases in sub-Saharan africa, 1990\u20132017: results from the global burden of disease study 2017. Lancet Glob Health. 2019;7:e1375\u201387.","journal-title":"Lancet Glob Health"},{"key":"9980_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes\u2013global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107.","journal-title":"J Epidemiol Glob Health"},{"key":"9980_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"9980_CR27","unstructured":"WHO, Obesity. and Overweight. 2020 [cited 29 Apr 2021]. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"9980_CR28","doi-asserted-by":"publisher","unstructured":"Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in africa: a hidden danger. Glob Health Epidemiol Genom. 2019;4:e3. https:\/\/doi.org\/10.1017\/gheh.2019.2","DOI":"10.1017\/gheh.2019.2"},{"key":"9980_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7196\/SAMJ.1422","volume":"100","author":"FC Kruger","year":"2010","unstructured":"Kruger FC, Daniels C, Kidd M, Swart G, Brundyn K, Van Rensburg C, et al. Non-alcoholic fatty liver disease (NAFLD) in the Western cape: a descriptive analysis. SAMJ: South Afr Med J. 2010;100:168\u201371.","journal-title":"SAMJ: South Afr Med J"},{"key":"9980_CR30","doi-asserted-by":"publisher","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022:7(9):851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"9980_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17:365.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"9980_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/JOMES23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated steatotic liver disease (MASLD): A State-of-the-Art review. J Obes Metab Syndr. 2023;32:197\u2013213. https:\/\/doi.org\/10.7570\/JOMES23052.","journal-title":"J Obes Metab Syndr"},{"key":"9980_CR33","doi-asserted-by":"publisher","unstructured":"Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol. 2023:78(2):415\u2013429. https:\/\/doi.org\/10.1016\/j.jhep.2022.09.020","DOI":"10.1016\/j.jhep.2022.09.020"},{"key":"9980_CR34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3892\/IJMM.2020.4479","volume":"45","author":"H Gao","year":"2020","unstructured":"Gao H, Cao Y, Xia H, Zhu X, Jin Y. CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROSinduced lipid peroxidation and inflammation. Int J Mol Med. 2020;45:1121\u20139. https:\/\/doi.org\/10.3892\/IJMM.2020.4479.","journal-title":"Int J Mol Med"},{"key":"9980_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","volume":"28","author":"NE Sunny","year":"2017","unstructured":"Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metabolism. 2017;28:250\u201360.","journal-title":"Trends Endocrinol Metabolism"},{"key":"9980_CR36","doi-asserted-by":"publisher","unstructured":"Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology. 2024 [cited 4 Apr 2025]. https:\/\/doi.org\/10.1097\/HEP.0000000000000786","DOI":"10.1097\/HEP.0000000000000786"},{"key":"9980_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","volume":"20","author":"J Schw\u00e4rzler","year":"2024","unstructured":"Schw\u00e4rzler J, Grabherr F, Grander C, Adolph TE, Tilg H. The pathophysiology of MASLD: an immunometabolic perspective. Expert Rev Clin Immunol. 2024;20:375\u201386. https:\/\/doi.org\/10.1080\/1744666X.2023.2294046.","journal-title":"Expert Rev Clin Immunol"},{"key":"9980_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12944-024-02108-X","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Disease 2024. 2024;23:1. https:\/\/doi.org\/10.1186\/S12944-024-02108-X.","journal-title":"Lipids Health Disease 2024"},{"key":"9980_CR39","doi-asserted-by":"publisher","first-page":"154708","DOI":"10.1016\/j.metabol.2021.154708","volume":"117","author":"M Longo","year":"2021","unstructured":"Longo M, Meroni M, Paolini E, Macchi C, Dongiovanni P. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metabolism. 2021;117:154708.","journal-title":"Metabolism"},{"key":"9980_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","volume":"76","author":"F Bessone","year":"2019","unstructured":"Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99\u2013128.","journal-title":"Cell Mol Life Sci"},{"key":"9980_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"key":"9980_CR42","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.","journal-title":"Metabolism"},{"key":"9980_CR43","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","volume":"38","author":"MR Jain","year":"2018","unstructured":"Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, et al. Dual PPAR \u03b1\/\u03b3 agonist Saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38:1084\u201394.","journal-title":"Liver Int"},{"key":"9980_CR44","doi-asserted-by":"publisher","first-page":"9547613","DOI":"10.1155\/2018\/9547613","volume":"2018","author":"M Masarone","year":"2018","unstructured":"Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613. https:\/\/doi.org\/10.1155\/2018\/9547613. 2018\/07\/12.","journal-title":"Oxid Med Cell Longev"},{"key":"9980_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-69764-y","volume":"14","author":"HA Osman","year":"2024","unstructured":"Osman HA, Abuhamdah SMA, Hassan MH, Hashim AA, Ahmed AE, Elsayed SS, et al. NLRP3 inflammasome pathway involved in the pathogenesis of metabolic associated fatty liver disease. Sci Rep 2024. 2024;14:1. https:\/\/doi.org\/10.1038\/s41598-024-69764-y.","journal-title":"Sci Rep 2024"},{"key":"9980_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2025.02.033","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/J.JHEP.2025.02.033. [cited 8 Apr 2025].","journal-title":"J Hepatol"},{"key":"9980_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","volume":"13","author":"JP Arab","year":"2018","unstructured":"Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321\u201350.","journal-title":"Annu Rev Pathol"},{"key":"9980_CR48","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1021\/ACSNANO.3C06107\/ASSET","volume":"18","author":"J Shinn","year":"2024","unstructured":"Shinn J, Park S, Lee S, Park N, Kim S, Hwang S, et al. Antioxidative hyaluronic Acid-Bilirubin nanomedicine targeting activated hepatic stellate cells for Anti-Hepatic-Fibrosis therapy. ACS Nano. 2024;18:4704\u201316. https:\/\/doi.org\/10.1021\/ACSNANO.3C06107\/ASSET\/IMAGES\/LARGE\/NN3C06107_0006.JPEG.","journal-title":"ACS Nano"},{"key":"9980_CR49","doi-asserted-by":"publisher","unstructured":"Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med. 2021;9. https:\/\/doi.org\/10.21037\/atm-20-4354.","DOI":"10.21037\/atm-20-4354"},{"key":"9980_CR50","doi-asserted-by":"publisher","unstructured":"Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, et al. Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20081948.","DOI":"10.3390\/ijms20081948"},{"key":"9980_CR51","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"9980_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jclinpath-2021-207967","volume":"75","author":"CR Langford","year":"2022","unstructured":"Langford CR, Goldinger MH, Treanor D, McGenity C, Dillman JR, Allende DS, et al. Improved pathology reporting in NAFLD\/NASH for clinical trials. J Clin Pathol. 2022;75:73\u20135.","journal-title":"J Clin Pathol"},{"key":"9980_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cld.924","volume":"16","author":"T Tariq","year":"2020","unstructured":"Tariq T, Desai AP. Nonalcoholic fatty liver disease: making the diagnosis. Clin Liver Dis (Hoboken). 2020;16:53.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"9980_CR54","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17474124.2020.1731303","volume":"14","author":"O El Sherif","year":"2020","unstructured":"El Sherif O, Dhaliwal A, Newsome PN, Armstrong MJ. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. Expert Rev Gastroenterol Hepatol. 2020;14:197\u2013205.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"9980_CR55","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MCG.0000000000001172","volume":"54","author":"D Hester","year":"2020","unstructured":"Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among medicare patients with hepatocellular carcinoma, non\u2013alcoholic fatty liver disease is the most common etiology and cause of mortality. J Clin Gastroenterol. 2020;54:459\u201367.","journal-title":"J Clin Gastroenterol"},{"key":"9980_CR56","doi-asserted-by":"publisher","unstructured":"Bhurosy T, Jeewon R. Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status? Sci World J. 2014;(1):964236. https:\/\/doi.org\/10.1155\/2014\/964236","DOI":"10.1155\/2014\/964236"},{"key":"9980_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0140-6736(11)60813-1","volume":"378","author":"BA Swinburn","year":"2011","unstructured":"Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804\u201314.","journal-title":"Lancet"},{"key":"9980_CR58","doi-asserted-by":"publisher","first-page":"S610","DOI":"10.1080\/07315724.2004.10719431","volume":"23","author":"DJ Hoffman","year":"2004","unstructured":"Hoffman DJ. Upper limits in developing countries: warning against too much in lands of too little. J Am Coll Nutr. 2004;23:S610\u20135.","journal-title":"J Am Coll Nutr"},{"key":"9980_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"M Ng","year":"2025","unstructured":"Ng M, Gakidou E, Lo J, Abate YH, Abbafati C, Abbas N, et al. Global, regional, and National prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021. Lancet. 2025;405:813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1.","journal-title":"Lancet"},{"key":"9980_CR60","doi-asserted-by":"publisher","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. https:\/\/doi.org\/10.21037\/thg.2019.09.08.","DOI":"10.21037\/thg.2019.09.08."},{"key":"9980_CR61","doi-asserted-by":"publisher","unstructured":"Ghemrawi R, Battaglia-Hsu SF, Arnold C. Endoplasmic Reticulum Stress in Metabolic Disorders. Cells. 2018\/06\/21. 2018;7. https:\/\/doi.org\/10.3390\/cells7060063","DOI":"10.3390\/cells7060063"},{"key":"9980_CR62","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1016\/j.sjbs.2021.05.063","volume":"28","author":"AS Alamri","year":"2021","unstructured":"Alamri AS, Alhomrani M, Alsanie WF, Alghamdi AJ, Alghamdi ZM, Al-Subaie AA, et al. Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of taif, Saudi arabia: A retrospective study. Saudi J Biol Sci. 2021;28:4921\u20135.","journal-title":"Saudi J Biol Sci"},{"key":"9980_CR63","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2174\/1381612822666161006151134","volume":"23","author":"D Nikolic","year":"2017","unstructured":"Nikolic D, Castellino G, Banach M, Toth PP, Ivanova E, Orekhov AN, et al. PPAR agonists, atherogenic dyslipidemia and cardiovascular risk. Curr Pharm Des. 2017;23:894\u2013902. https:\/\/doi.org\/10.2174\/1381612822666161006151134. 2016\/10\/11.","journal-title":"Curr Pharm Des"},{"key":"9980_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev.publhealth.26.021304.144628","volume":"26","author":"EA Finkelstein","year":"2005","unstructured":"Finkelstein EA, Ruhm CJ, Kosa KM. Economic causes and consequences of obesity. Annu Rev Public Health. 2005;26:239\u201357.","journal-title":"Annu Rev Public Health"},{"key":"9980_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.orcp.2016.03.009","volume":"12","author":"ASB Jorge","year":"2018","unstructured":"Jorge ASB, Andrade JMO, Para\u00edso AF, Jorge GCB, Silveira CM, de Souza LR, et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obes Res Clin Pract. 2018;12:1\u20138. https:\/\/doi.org\/10.1016\/j.orcp.2016.03.009.","journal-title":"Obes Res Clin Pract"},{"key":"9980_CR66","doi-asserted-by":"publisher","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de Novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130. https:\/\/doi.org\/10.1172\/JCI134165.","DOI":"10.1172\/JCI134165"},{"key":"9980_CR67","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/J.MOLMET.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. https:\/\/doi.org\/10.1016\/J.MOLMET.2021.101238.","journal-title":"Mol Metab"},{"key":"9980_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-48382-5_19","author":"A Engin","year":"2017","unstructured":"Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol. 2017. https:\/\/doi.org\/10.1007\/978-3-319-48382-5_19.","journal-title":"Adv Exp Med Biol"},{"key":"9980_CR69","doi-asserted-by":"publisher","unstructured":"Nikolic D, Castellino G, Banach M, Toth P, Ivanova E, Orekhov A, et al. PPAR agonists, atherogenic dyslipidemia and cardiovascular risk. Curr Pharm Des. 2016;23. https:\/\/doi.org\/10.2174\/1381612822666161006151134.","DOI":"10.2174\/1381612822666161006151134"},{"key":"9980_CR70","doi-asserted-by":"publisher","first-page":"610","DOI":"10.7150\/ijbs.29599","volume":"15","author":"R Divella","year":"2019","unstructured":"Divella R, Mazzocca A, Daniele A, Sabb\u00e0 C, Paradiso A. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. Int J Biol Sci. 2019;15:610.","journal-title":"Int J Biol Sci"},{"key":"9980_CR71","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.1.33","author":"C Boutari","year":"2018","unstructured":"Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metabolism. 2018. https:\/\/doi.org\/10.3803\/EnM.2018.33.1.33.","journal-title":"Endocrinol Metabolism"},{"key":"9980_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6020052","author":"T Gamberi","year":"2018","unstructured":"Gamberi T, Magherini F, Modesti A, Fiaschi T. Adiponectin signaling pathways in liver diseases. Biomedicines. 2018. https:\/\/doi.org\/10.3390\/biomedicines6020052.","journal-title":"Biomedicines"},{"key":"9980_CR73","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms18081649","volume":"18","author":"TE Adolph","year":"2017","unstructured":"Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18:1649.","journal-title":"Int J Mol Sci"},{"key":"9980_CR74","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263.","journal-title":"World J Gastroenterol"},{"key":"9980_CR75","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063\u201372.","journal-title":"N Engl J Med"},{"key":"9980_CR76","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41401-022-00874-x","volume":"43","author":"X Tong","year":"2022","unstructured":"Tong X, Wang Q, Zhao X, Sun Y, Wu X, Yang L, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43:1200\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"9980_CR77","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"9980_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123860","author":"M Parra-Vargas","year":"2020","unstructured":"Parra-Vargas M, Rodriguez-Echevarria R, Jimenez-Chillaron JC. Nutritional approaches for the management of nonalcoholic fatty liver disease: an evidence-based review. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12123860.","journal-title":"Nutrients"},{"key":"9980_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11892-025-01579-1","volume":"25","author":"MW Takawy","year":"2025","unstructured":"Takawy MW, Abdelmalek MF. Impact of weight loss on metabolic dysfunction associated steatohepatitis and hepatic fibrosis. Curr Diabetes Rep 2025. 2025;25:1. https:\/\/doi.org\/10.1007\/S11892-025-01579-1.","journal-title":"Curr Diabetes Rep 2025"},{"key":"9980_CR80","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380. https:\/\/doi.org\/10.1002\/hep.29086. 2017\/01\/29.","journal-title":"Hepatology"},{"key":"9980_CR81","doi-asserted-by":"publisher","first-page":"13219","DOI":"10.3390\/ijms222413219","volume":"22","author":"B Filipovic","year":"2021","unstructured":"Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, et al. The new therapeutic approaches in the treatment of Non-Alcoholic fatty liver disease. Int J Mol Sci. 2021;22:13219.","journal-title":"Int J Mol Sci"},{"key":"9980_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13302","author":"AM Oseini","year":"2017","unstructured":"Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017. https:\/\/doi.org\/10.1111\/liv.13302.","journal-title":"Liver Int"},{"key":"9980_CR83","doi-asserted-by":"publisher","unstructured":"Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017;8. https:\/\/doi.org\/10.3389\/fendo.2017.00006.","DOI":"10.3389\/fendo.2017.00006"},{"key":"9980_CR84","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue Pegozafermin in NASH. N Engl J Med. 2023;389:998\u20131008.","journal-title":"N Engl J Med"},{"issue":"21","key":"9980_CR85","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic Dysfunction-Associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"key":"9980_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00507-z","author":"D Ferguson","year":"2021","unstructured":"Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Reviews Endocrinol. 2021. https:\/\/doi.org\/10.1038\/s41574-021-00507-z.","journal-title":"Nat Reviews Endocrinol"},{"key":"9980_CR87","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175\u201383.","journal-title":"JAMA"},{"key":"9980_CR88","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70:711\u201324.","journal-title":"Hepatology"},{"key":"9980_CR89","doi-asserted-by":"publisher","unstructured":"Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide\u20101 receptor agonists (GLP\u20101 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review. Endocrinol Diabetes Metab. 2020;3(3):e00163. https:\/\/doi.org\/10.1002\/edm2.163.","DOI":"10.1002\/edm2.163."},{"key":"9980_CR90","doi-asserted-by":"publisher","unstructured":"Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int. 2021;41. https:\/\/doi.org\/10.1111\/liv.14888.","DOI":"10.1111\/liv.14888"},{"key":"9980_CR91","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.3390\/ijms19102863","volume":"19","author":"J Zhou","year":"2018","unstructured":"Zhou J, Massey S, Story D, Li L. Metformin: an old drug with new applications. Int J Mol Sci. 2018;19:2863.","journal-title":"Int J Mol Sci"},{"key":"9980_CR92","doi-asserted-by":"publisher","first-page":"120956","DOI":"10.1016\/j.lfs.2022.120956","volume":"308","author":"HH Shaaban","year":"2022","unstructured":"Shaaban HH, Alzaim I, El-Mallah A, Aly RG, El-Yazbi AF, Wahid A. Metformin, pioglitazone, Dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. Life Sci. 2022;308:120956.","journal-title":"Life Sci"},{"key":"9980_CR93","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","volume":"178","author":"G Della Pepa","year":"2021","unstructured":"Della Pepa G, Russo M, Vitale M, Carli F, Vetrani C, Masulli M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA. IT randomised trial. Diabetes Res Clin Pract. 2021;178:108984.","journal-title":"Diabetes Res Clin Pract"},{"key":"9980_CR94","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/molecules27030727","volume":"27","author":"J Ren","year":"2022","unstructured":"Ren J, Wang X, Yee C, Gorrell MD, McLennan SV, Twigg SM. Sitagliptin is more effective than Gliclazide in preventing pro-fibrotic and pro-inflammatory changes in a rodent model of diet-induced non-alcoholic fatty liver disease. Molecules. 2022;27:727.","journal-title":"Molecules"},{"key":"9980_CR95","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","volume":"284","author":"F Nascimbeni","year":"2019","unstructured":"Nascimbeni F, Pellegrini E, Lugari S, Mondelli A, Bursi S, Onfiani G, et al. Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes. Atherosclerosis. 2019;284:66\u201374.","journal-title":"Atherosclerosis"},{"key":"9980_CR96","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","volume":"116","author":"JI Lee","year":"2021","unstructured":"Lee JI, Lee HW, Lee KS, Lee HS, Park J-Y. Effects of Statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Official J Am Coll Gastroenterology| ACG. 2021;116:116\u201324.","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"key":"9980_CR97","first-page":"S547","volume":"116","author":"S Trujillo","year":"2021","unstructured":"Trujillo S, Kamionkowski S, Walsh E, Davila J, Asaad I. S1175 do weight loss medications reduce the risk of cirrhosis and HCC? Official J Am Coll Gastroenterology| ACG. 2021;116:S547\u20138.","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"key":"9980_CR98","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/hep.22575","volume":"49","author":"SA Harrison","year":"2009","unstructured":"Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80\u20136.","journal-title":"Hepatology"},{"key":"9980_CR99","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ncp.10449","volume":"35","author":"MS Mundi","year":"2020","unstructured":"Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35:72\u201384.","journal-title":"Nutr Clin Pract"},{"key":"9980_CR100","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/ph11040104","volume":"11","author":"L Abenavoli","year":"2018","unstructured":"Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease. Pharmaceuticals. 2018;11:104.","journal-title":"Pharmaceuticals"},{"key":"9980_CR101","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41575-020-0264-1","volume":"17","author":"J Hindson","year":"2020","unstructured":"Hindson J. Obeticholic acid for the treatment of NASH. Nat Rev Gastroenterol Hepatol. 2020;17:66.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9980_CR102","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/liv.14888","volume":"41","author":"N Perakakis","year":"2021","unstructured":"Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int. 2021;41:1853\u201366.","journal-title":"Liver Int"},{"key":"9980_CR103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","volume":"29","author":"MJ Van Westerouen","year":"2020","unstructured":"Van Westerouen MJ, Drenth JPH, Tjwa ETTL. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29:117\u201323.","journal-title":"Expert Opin Investig Drugs"},{"key":"9980_CR104","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator\u2013\u2009activated receptor\u2013 \u03b1 and\u2013 \u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147\u201359.","journal-title":"Gastroenterology"},{"key":"9980_CR105","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/13543784.2018.1442436","volume":"27","author":"F Tacke","year":"2018","unstructured":"Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27:301\u201311.","journal-title":"Expert Opin Investig Drugs"},{"key":"9980_CR106","doi-asserted-by":"publisher","unstructured":"Neokosmidis G, Tziomalos K. Role of cenicriviroc in the management of nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24. https:\/\/doi.org\/10.3748\/wjg.v24.i48.5415.","DOI":"10.3748\/wjg.v24.i48.5415"},{"key":"9980_CR107","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with Selonsertib. Liver Int. 2018;38. https:\/\/doi.org\/10.1111\/liv.13706.","DOI":"10.1111\/liv.13706"},{"key":"9980_CR108","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.redox.2020.101710","volume":"37","author":"MC Podszun","year":"2020","unstructured":"Podszun MC, Alawad AS, Lingala S, Morris N, Huang W-CA, Yang S, et al. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biol. 2020;37:101710.","journal-title":"Redox Biol"},{"key":"9980_CR109","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/diseases6040086","volume":"6","author":"BJ Perumpail","year":"2018","unstructured":"Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, et al. The role of vitamin E in the treatment of NAFLD. Diseases. 2018;6:86.","journal-title":"Diseases"},{"key":"9980_CR110","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/ijms22052350","volume":"22","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: state of Art. Int J Mol Sci. 2021;22:2350.","journal-title":"Int J Mol Sci"},{"key":"9980_CR111","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7614270","author":"D Alem\u00e1n-Gonz\u00e1lez-Duhart","year":"2016","unstructured":"Alem\u00e1n-Gonz\u00e1lez-Duhart D, Tamay-Cach F, \u00c1lvarez-Almaz\u00e1n S, Mendieta-Wejebe JE. Current advances in the biochemical and physiological aspects of the treatment of type 2 diabetes mellitus with Thiazolidinediones. PPAR Res. 2016. https:\/\/doi.org\/10.1155\/2016\/7614270.","journal-title":"PPAR Res"},{"key":"9980_CR112","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2016.07.897","volume":"253","author":"P Chru\u015bciel","year":"2016","unstructured":"Chru\u015bciel P, Sahebkar A, Rembek-Wieliczko M, Serban M-C, Ursoniu S, Mikhailidis DP, et al. Impact of Statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194\u2013208.","journal-title":"Atherosclerosis"},{"key":"9980_CR113","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 inhibitor Selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67:549\u201359.","journal-title":"Hepatology"},{"key":"9980_CR114","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cld.2017.08.013","volume":"22","author":"S Gawrieh","year":"2018","unstructured":"Gawrieh S, Chalasani N. Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22:189\u201399.","journal-title":"Clin Liver Dis"},{"key":"9980_CR115","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"9980_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.07.034","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018. https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.034.","journal-title":"Eur J Pharmacol"},{"key":"9980_CR117","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cells9030785","volume":"9","author":"WI Effendi","year":"2020","unstructured":"Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells. 2020;9:785.","journal-title":"Cells"},{"key":"9980_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113888","author":"V Kumar","year":"2021","unstructured":"Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2021. https:\/\/doi.org\/10.1016\/j.addr.2021.113888.","journal-title":"Adv Drug Deliv Rev"},{"key":"9980_CR119","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1021\/acsnano.1c02158","volume":"15","author":"R Tang","year":"2021","unstructured":"Tang R, Li R, Li H, Ma X-L, Du P, Yu X-Y, et al. Design of hepatic targeted drug delivery systems for natural products: insights into nomenclature revision of nonalcoholic fatty liver disease. ACS Nano. 2021;15:17016\u201346.","journal-title":"ACS Nano"},{"key":"9980_CR120","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","volume":"9","author":"K Naran","year":"2018","unstructured":"Naran K, Nundalall T, Chetty S, Barth S. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. Front Microbiol. 2018;9:3158.","journal-title":"Front Microbiol"},{"key":"9980_CR121","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.addr.2021.04.003","volume":"173","author":"SA Salunkhe","year":"2021","unstructured":"Salunkhe SA, Chitkara D, Mahato RI, Mittal A. Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. Adv Drug Deliv Rev. 2021;173:394\u2013415.","journal-title":"Adv Drug Deliv Rev"},{"key":"9980_CR122","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.trecan.2018.03.004","volume":"4","author":"E Lengyel","year":"2018","unstructured":"Lengyel E, Makowski L, Digiovanni J, Kolonin MG. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors the Cancer-Obesity Link-Epidemiologic evidence HHS public access. Trends Cancer. 2018;4:374\u201384. https:\/\/doi.org\/10.1016\/j.trecan.2018.03.004.","journal-title":"Trends Cancer"},{"key":"9980_CR123","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.mehy.2004.01.046","volume":"63","author":"O Dizdar","year":"2004","unstructured":"Dizdar O, Alyama\u00e7 E. Obesity: an endocrine tumor? Med Hypotheses. 2004;63:790\u20132. https:\/\/doi.org\/10.1016\/j.mehy.2004.01.046.","journal-title":"Med Hypotheses"},{"key":"9980_CR124","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-022-05030-3","volume":"608","author":"T Seki","year":"2022","unstructured":"Seki T, Yang Y, Sun X, Lim S, Xie S, Guo Z, et al. Brown-fat-mediated tumour suppression by cold-altered global metabolism. Nature. 2022;608:421\u20138. https:\/\/doi.org\/10.1038\/s41586-022-05030-3.","journal-title":"Nature"},{"key":"9980_CR125","doi-asserted-by":"publisher","unstructured":"Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10. https:\/\/doi.org\/10.1038\/nm1048.","DOI":"10.1038\/nm1048"},{"key":"9980_CR126","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11051-015-2904-x","volume":"17","author":"N Thovhogi","year":"2015","unstructured":"Thovhogi N, Sibuyi N, Meyer M, Onani M, Madiehe A. Targeted delivery using peptide-functionalised gold nanoparticles to white adipose tissues of obese rats. J Nanopart Res. 2015;17:112. https:\/\/doi.org\/10.1007\/s11051-015-2904-x.","journal-title":"J Nanopart Res"},{"key":"9980_CR127","doi-asserted-by":"publisher","unstructured":"Pellegata NS, Berriel Diaz M, Rohm M, Herzig S. Obesity and cancer\u2014extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases. Cancer Metastasis Rev. 2022;41(3):517\u2013547. https:\/\/doi.org\/10.1007\/s10555-022-10058-y","DOI":"10.1007\/s10555-022-10058-y"},{"key":"9980_CR128","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2217\/nnm-2017-0085","volume":"12","author":"S Sibuyi","year":"2017","unstructured":"Sibuyi S, Thovhogi NR, Gabuza N, Meyer KB, Drah MD, Onani M. Peptide-functionalized nanoparticles for the selective induction of apoptosis in target cells. Nanomedicine. 2017;12:1631\u201345.","journal-title":"Nanomedicine"},{"key":"9980_CR129","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/IJN.S158687","volume":"13","author":"N Thovhogi","year":"2018","unstructured":"Thovhogi N, Sibuyi NRSNNRS, Onani MOM, Meyer M, Madiehe AMAAM. Peptide-functionalized quantum Dots for potential applications in the imaging and treatment of obesity. Int J Nanomed. 2018;13:2551\u20139. https:\/\/doi.org\/10.2147\/IJN.S158687.","journal-title":"Int J Nanomed"},{"key":"9980_CR130","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/ph14030215","volume":"14","author":"R Abou Assi","year":"2021","unstructured":"Abou Assi R, Abdulbaqi IM, Siok Yee C. The evaluation of drug delivery nanocarrier development and Pharmacological briefing for metabolic-associated fatty liver disease (MAFLD): an update. Pharmaceuticals. 2021;14:215.","journal-title":"Pharmaceuticals"},{"key":"9980_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0554-3","volume":"17","author":"NRS Sibuyi","year":"2019","unstructured":"Sibuyi NRS, Moabelo KL, Meyer M, Onani MO, Dube A, Madiehe AM. Nanotechnology advances towards development of targeted-treatment for obesity. J Nanobiotechnol. 2019;17:1\u201321.","journal-title":"J Nanobiotechnol"},{"key":"9980_CR132","doi-asserted-by":"publisher","first-page":"7915","DOI":"10.2147\/IJN.S173424","volume":"13","author":"NRS Sibuyi","year":"2018","unstructured":"Sibuyi NRS, Meyer M, Onani MO, Skepu A, Madiehe AM. Vascular targeted nanotherapeutic approach for obesity treatment. Int J Nanomed. 2018;13:7915.","journal-title":"Int J Nanomed"},{"key":"9980_CR133","doi-asserted-by":"publisher","first-page":"9223","DOI":"10.1021\/acsnano.7b04348","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu Q, Yu J, Yu S, Wang J, Qiang L, et al. Locally induced adipose tissue Browning by microneedle patch for obesity treatment. ACS Nano. 2017;11:9223\u201330.","journal-title":"ACS Nano"},{"key":"9980_CR134","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.ymthe.2017.05.020","volume":"25","author":"C Jiang","year":"2017","unstructured":"Jiang C, Cano-Vega MA, Yue F, Kuang L, Narayanan N, Uzunalli G, et al. Dibenzazepine-loaded nanoparticles induce local Browning of white adipose tissue to counteract obesity. Mol Ther. 2017;25:1718\u201329.","journal-title":"Mol Ther"},{"key":"9980_CR135","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1021\/acsbiomaterials.7b00549","volume":"3","author":"JH Lee","year":"2017","unstructured":"Lee JH, Jeong HS, Lee DH, Beack S, Kim T, Lee G-H, et al. Targeted hyaluronate\u2013hollow gold nanosphere conjugate for anti-obesity photothermal lipolysis. ACS Biomater Sci Eng. 2017;3:3646\u201353.","journal-title":"ACS Biomater Sci Eng"},{"key":"9980_CR136","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1021\/acsami.0c05750","volume":"13","author":"S Ni","year":"2021","unstructured":"Ni S, Zhuo Z, Pan Y, Yu Y, Li F, Liu J, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces. 2021;13:9500\u201319. https:\/\/doi.org\/10.1021\/acsami.0c05750.","journal-title":"ACS Appl Mater Interfaces"},{"key":"9980_CR137","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2012.09.002","volume":"163","author":"MN Hossen","year":"2012","unstructured":"Hossen MN, Kajimoto K, Akita H, Hyodo M, Harashima H. Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery. J Controlled Release. 2012;163:101\u201310. https:\/\/doi.org\/10.1016\/j.jconrel.2012.09.002.","journal-title":"J Controlled Release"},{"key":"9980_CR138","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1021\/acsnano.1c08690","volume":"16","author":"X Chen","year":"2021","unstructured":"Chen X, He X, Gao R, Lan X, Zhu L, Chen K, et al. Aptamer-Functionalized Binary-Drug delivery system for synergetic obesity therapy. ACS Nano. 2021;16:1036\u201350.","journal-title":"ACS Nano"},{"key":"9980_CR139","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jconrel.2013.07.013","volume":"171","author":"MN Hossen","year":"2013","unstructured":"Hossen MN, Kajimoto K, Akita H, Hyodo M, Harashima H. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. J Controlled Release. 2013;171:104\u201312.","journal-title":"J Controlled Release"},{"key":"9980_CR140","doi-asserted-by":"publisher","unstructured":"Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab. 2021;12. https:\/\/doi.org\/10.1177\/20420188211034300.","DOI":"10.1177\/20420188211034300"},{"key":"9980_CR141","doi-asserted-by":"publisher","unstructured":"Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, et al. Targeting liver fibrosis with a cell-penetrating protease-activated receptor-2 (PAR2) pepducin. J Biol Chem. 2016;291. https:\/\/doi.org\/10.1074\/jbc.M116.732743.","DOI":"10.1074\/jbc.M116.732743"},{"key":"9980_CR142","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1021\/acs.analchem.0c04866","volume":"93","author":"Y Pu","year":"2021","unstructured":"Pu Y, Xiang J, Zhang X, Deng Y, Liu H, Tan W. CD36 as a molecular target of functional DNA aptamer NAFLD01 selected against NAFLD cells. Anal Chem. 2021;93:3951\u20138.","journal-title":"Anal Chem"},{"key":"9980_CR143","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1021\/ACS.ANALCHEM.0C04866\/SUPPL_FILE\/AC0C04866_SI_001.PDF","volume":"93","author":"Y Pu","year":"2021","unstructured":"Pu Y, Liu H, Tan W, Xiang J, Zhang X, Deng Y. CD36 as a molecular target of functional DNA aptamer NAFLD01 selected against NAFLD cells. Anal Chem. 2021;93:3951\u20138. https:\/\/doi.org\/10.1021\/ACS.ANALCHEM.0C04866\/SUPPL_FILE\/AC0C04866_SI_001.PDF.","journal-title":"Anal Chem"},{"key":"9980_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2019.04.004","author":"GI Ash","year":"2019","unstructured":"Ash GI, Kim D, Choudhury M. Promises of nanotherapeutics in obesity. Trends Endocrinol Metabolism. 2019. https:\/\/doi.org\/10.1016\/j.tem.2019.04.004.","journal-title":"Trends Endocrinol Metabolism"},{"key":"9980_CR145","doi-asserted-by":"publisher","unstructured":"Fadaka AO, Akinsoji T, Klein A, Madiehe AM, Meyer M, Keyster M et al. Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach. J Pharm Anal. 2023;13(11):1235\u20131251. https:\/\/doi.org\/10.1016\/j.jpha.2023.07.008.","DOI":"10.1016\/j.jpha.2023.07.008."},{"key":"9980_CR146","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.7150\/ijbs.59588","volume":"17","author":"Z Fang","year":"2021","unstructured":"Fang Z, Dou G, Wang L. MicroRNAs in the pathogenesis of nonalcoholic fatty liver disease. Int J Biol Sci. 2021;17:1851.","journal-title":"Int J Biol Sci"},{"key":"9980_CR147","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/cells9041041","volume":"9","author":"H-Y Lin","year":"2020","unstructured":"Lin H-Y, Yang Y-L, Wang P-W, Wang F-S, Huang Y-H. The emerging role of MicroRNAs in NAFLD: highlight of microRNA-29a in modulating oxidative stress, inflammation, and beyond. Cells. 2020;9:1041.","journal-title":"Cells"},{"key":"9980_CR148","doi-asserted-by":"publisher","first-page":"527059","DOI":"10.3389\/fmed.2020.527059","volume":"7","author":"AR L\u00f3pez-Pastor","year":"2020","unstructured":"L\u00f3pez-Pastor AR, Infante-Men\u00e9ndez J, Escribano \u00d3, G\u00f3mez-Hern\u00e1ndez A. MiRNA dysregulation in the development of non-alcoholic fatty liver disease and the related disorders type 2 diabetes mellitus and cardiovascular disease. Front Med (Lausanne). 2020;7:527059.","journal-title":"Front Med (Lausanne)"},{"key":"9980_CR149","doi-asserted-by":"publisher","unstructured":"Chen K, Cheong LY, Gao Y, Zhang Y, Feng T, Wang Q, et al. Adipose-targeted Triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects. Nat Commun. 2022;13. https:\/\/doi.org\/10.1038\/s41467-022-35470-4.","DOI":"10.1038\/s41467-022-35470-4"},{"key":"9980_CR150","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1039\/D0CC00513D","volume":"56","author":"Z Wang","year":"2020","unstructured":"Wang Z, Ma C, Shang Y, Yang L, Zhang J, Yang C, et al. Simultaneous co-assembly of Fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD). Chem Commun. 2020;56:4922\u20135.","journal-title":"Chem Commun"},{"key":"9980_CR151","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fchem.2020.00407","volume":"8","author":"R Zhao","year":"2020","unstructured":"Zhao R, Zhu M, Zhou S, Feng W, Chen H. Rapamycin-loaded mPEG-PLGA nanoparticles ameliorate hepatic steatosis and liver injury in non-alcoholic fatty liver disease. Front Chem. 2020;8:407.","journal-title":"Front Chem"},{"key":"9980_CR152","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41392-023-01430-7","volume":"8","author":"J Ma","year":"2023","unstructured":"Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X, et al. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:168.","journal-title":"Signal Transduct Target Ther"},{"key":"9980_CR153","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","volume":"25","author":"TS Zimmermann","year":"2017","unstructured":"Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017;25:71\u20138.","journal-title":"Mol Ther"},{"key":"9980_CR154","doi-asserted-by":"publisher","unstructured":"Unagolla J, Das S, Flanagan R, Oehler M, Menon JU. Targeting chronic liver diseases: molecular markers, drug delivery strategies and future perspectives. Int J Pharm 2024;660:124381. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124381.","DOI":"10.1016\/j.ijpharm.2024.124381."},{"key":"9980_CR155","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","volume":"19","author":"L Jiang","year":"2021","unstructured":"Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): structures and ligands. Comput Struct Biotechnol J. 2021;19:2148\u201359.","journal-title":"Comput Struct Biotechnol J"},{"key":"9980_CR156","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.3390\/molecules27238531","volume":"27","author":"AK Tonduru","year":"2022","unstructured":"Tonduru AK, Adla SK, Huttunen KM, Kronenberger T, Poso A. Comparative modelling of organic anion transporting polypeptides: structural insights and comparison of binding modes. Molecules. 2022;27:8531.","journal-title":"Molecules"},{"key":"9980_CR157","doi-asserted-by":"publisher","unstructured":"Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim J-H et al. Liver-targeted cyclosporine A-encapsulated Poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomed. 2015;10:903\u201321. https:\/\/doi.org\/10.2147\/IJN.S74723.","DOI":"10.2147\/IJN.S74723."},{"key":"9980_CR158","first-page":"792","volume":"11","author":"S Todisco","year":"2022","unstructured":"Todisco S, Santarsiero A, Convertini P, De Stefano G, Gilio M, Iacobazzi V, et al. PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Biology (Basel). 2022;11:792.","journal-title":"Biology (Basel)"},{"key":"9980_CR159","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.livres.2021.08.003","volume":"5","author":"M Biagioli","year":"2021","unstructured":"Biagioli M, Fiorucci S. Bile acid activated receptors: integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Res. 2021;5:119\u201341.","journal-title":"Liver Res"},{"key":"9980_CR160","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3389\/fphys.2020.00873","volume":"11","author":"E Pandey","year":"2020","unstructured":"Pandey E, Nour AS, Harris EN. Prominent receptors of liver sinusoidal endothelial cells in liver homeostasis and disease. Front Physiol. 2020;11:873.","journal-title":"Front Physiol"},{"key":"9980_CR161","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/jcm10071338","volume":"10","author":"L Lei","year":"2021","unstructured":"Lei L, EI Mourabit H, Housset C, Cadoret A, Lemoinne S. Role of angiogenesis in the pathogenesis of NAFLD. J Clin Med. 2021;10:1338.","journal-title":"J Clin Med"},{"key":"9980_CR162","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12935-024-03295-4","volume":"24","author":"F Mahmoudian","year":"2024","unstructured":"Mahmoudian F, Ahmari A, Shabani S, Sadeghi B, Fahimirad S, Fattahi F. Aptamers as an approach to targeted cancer therapy. Cancer Cell Int. 2024;24:108.","journal-title":"Cancer Cell Int"},{"key":"9980_CR163","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/pharmaceutics12070646","volume":"12","author":"P Kumar Kulabhusan","year":"2020","unstructured":"Kumar Kulabhusan P, Hussain B, Y\u00fcce M. Current perspectives on aptamers as diagnostic tools and therapeutic agents. Pharmaceutics. 2020;12:646.","journal-title":"Pharmaceutics"},{"key":"9980_CR164","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199.Aptamers","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges have a patent pending on Cell-specific internalizing RNA aptamers against human CCR5 and used therefore [United States Patent HHS Public Access. Nat Rev Drug Discov. 2017;16:181\u2013202. https:\/\/doi.org\/10.1038\/nrd.2016.199.Aptamers.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-09980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-025-09980-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-09980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:43:05Z","timestamp":1781606585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-025-09980-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":164,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9980"],"URL":"https:\/\/doi.org\/10.1007\/s11154-025-09980-7","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"11 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}